

IN THE SPECIFICATION:

Please replace the paragraph added by preliminary amendment at page 1, line 3, with the following rewritten paragraph:

This application is a divisional of co-pending U.S. Patent Application Serial No. 09/326,342 filed June 4, 1999, now U.S. Patent No. 6,663,862, incorporated herein by reference in its entirety

Please replace the paragraph beginning at page 20, line 1, with the following rewritten paragraph:

An alternative embodiment of a GB1 domain polypeptide of the present invention comprises mutations at a threonine [[35]]44 residue and at a tyrosine 45 residue of a native GB1 domain polypeptide. The mutation comprises a substitution of the threonine [[35]]44 residue and tyrosine 45 residue~~[[s]]~~ with any of the other 19 amino acids, as it is contemplated by the present inventors that any such substitution substantially abolishes Fc binding activity while maintaining Fab binding activity. Optionally, the substitution may comprise a comparatively non-polar amino acid residue, such as alanine, valine, leucine and isoleucine. A particularly contemplated example of such a GB1 polypeptide is disclosed in SEQ ID NO: 18.